Ingenol mebutate 0.015% gel is safe for short-term treatment of actinic keratoses on the face in solid organ transplant recipients.
Ingenol mebutate 0.015% gel is safe for short-term treatment of actinic keratoses on the face in solid organ transplant recipients.
Br J Dermatol. 2020 Mar 27;:
Authors: Crow LD, Yuan JT, Aroyan CS, Twigg AR, Singer JP, Roll GR, Lazar AA, Arron ST
Abstract
Immunosuppressed solid organ transplant recipients (SOTR) have a high burden of AK, but have been excluded from clinical trials of ingenol mebutate 0.015% gel. This leaves dermatologists and transplant teams to extrapolate safety data from immunocompetent patients or from two case reports of use in SOTR. This single-arm, open-label investigator-initiated study investigated the safety and tolerability of topical ingenol mebutate 0.015% gel in SOTR.
PMID: 32221965 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Crow LD, Yuan JT, Aroyan CS, Twigg AR, Singer JP, Roll GR, Lazar AA, Arron ST Tags: Br J Dermatol Source Type: research
More News: Clinical Trials | Dermatology | Skin | Study | Transplant Surgery | Transplants | UK Health